News

Low-dose metformin, a medication for type 2 diabetes, delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of pulmonary arterial hypertension (PAH) in rats, a study reports. “Administration of [metformin] nanocapsules is a safe and innovative therapeutic approach for PAH,” the researchers wrote. “This method could improve…

Plans for a Phase 2b clinical trial that will test CS1, Cereno Scientific‘s experimental treatment for pulmonary arterial hypertension (PAH), have been endorsed by the U.S. Food and Drug Administration (FDA). The FDA’s endorsement comes just a few weeks after a meeting between Cereno and the FDA…

The U.S. Food and Drug Administration (FDA) has approved Yutrepia, Liquidia’s inhaled dry powder formulation of treprostinil, for improving exercise capacity in people with pulmonary hypertension (PH) associated with interstitial lung disease, known as PH-ILD, and pulmonary arterial hypertension, or PAH. Yutrepia had previously held tentative approvals…

The U.S. Food and Drug Administration (FDA) has granted breakthrough device status to the Gradient Denervation System, an ultrasound-based catheter for treating pulmonary hypertension (PH). A breakthrough designation is given to medical devices that may offer significant advantages over existing treatments for irreversibly debilitating or life-threatening conditions. It’s intended…

Most people with pulmonary arterial hypertension (PAH) who were treated with Uptravi (selexipag) and followed up for 10 years in an extension study are still alive, according to new data. Adding two other types of PAH therapy or starting triple therapy within six months of a diagnosis…

Nearly two-thirds of patients with left ventricular diastolic dysfunction (LVDD) — in which the heart struggles to relax and fill with blood between heartbeats — also have pulmonary hypertension, a study found, and the condition is more likely if a person has an enlarged left atrium (the heart’s upper…

The first participant has been dosed in a Phase 2 trial testing the experimental oral therapy mirivadelgat in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Phase 2 trial, called WINDWARD (NCT06475781), aims to enroll about 126 adults with PH-ILD, ages 18 to 85. Participants will…

Treatment with Opsynvi (macitentan and tadalafil) as a single-tablet combination therapy for people with pulmonary arterial hypertension (PAH) is highly valued by patients and endorsed by clinicians, according to interviews conducted during the Phase 3 A DUE trial. All patients interviewed said that a single, once-a-day pill to…

Corvista Health’s machine-learned algorithm can accurately diagnose pulmonary hypertension (PH) in a noninvasive way by assessing the elevation of mean pulmonary arterial pressure (mPAP), a study showed. The point-of-care system is based on a procedure that can be conducted during medical appointments in under five minutes, with patients…

Combining pulmonary vasodilators, medications that widen blood vessels, and antifibrotics, which slow the progression of scarring, may prolong survival and time without needing a transplant in people with both pulmonary hypertension (PH) and pulmonary fibrosis, a study suggested. “Antifibrotic and pulmonary vasodilator therapy could improve transplant-free survival in…

Reducing the levels of the protein NEK2 in the pulmonary arteries lessened disease-driving changes in blood vessels and the heart of a rat model of pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD). The effects were tied to a modulation of the NF-kB pathway involved in vascular…

Synhale Therapeutics has acquired the rights to the experimental therapy telaglenastat (CB-839), which has previously been tested as a potential cancer therapy. The company is planning to launch a Phase 2 clinical trial to test telaglenastat in people with pulmonary hypertension (PH). “This acquisition represents a unique opportunity to…